Health Care Equipment & Supplies

Abbott announced U.S. Food and Drug Administration approval for updates to its CardioMEMS HF System that, for the first time, let U.S. CardioMEMS patients view their pulmonary artery pressure readings directly on their smartphones through the new CardioGuide HF App. The new capabilities also include Dynamic Treatment Plan, a software feature that lets clinicians set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure and send medication adjustment instructions directly to patients through the app. The CardioMEMS HF System, which measures pulmonary artery pressure through an implanted sensor in the pulmonary artery, has been shown to reduce heart failure hospitalizations and mortality risk, and clinicians have used its readings for more than a decade to identify signs of worsening heart failure and guide treatment. Abbott said it plans to make the CardioGuide HF App and Dynamic Treatment Plan available later this year. Katie Spayde, vice president of Abbott's heart failure division, said the new capabilities help patients stay informed, engaged and connected to their care between doctor visits.

AtriCure's fair value price target has shifted from about US$51.67 to about US$54.89, reflecting modest fine tuning in analyst models rather than a wholesale reset. BTIG raised its AtriCure price target to US$55 from US$45, pointing to the new STS Quality Metric, which it thinks could support greater use of the EnCompass Clamp in U.S. surgery patients with preoperative atrial fibrillation, and noting that only about 35% of atrial fibrillation patients undergoing cardiac surgery in the U.S. currently receive a surgical ablation. BTIG models potential upside to AtriCure's U.S. Open Ablation revenue of US$10m to US$25m in 2027 and US$20m to US$55m in 2028 compared with its prior forecasts. UBS keeps a Buy rating on AtriCure alongside a revised price target of US$50 from US$55, citing business growth excluding MIS as support for what it describes as sustainable double digit top line expansion. Freedom Capital downgraded AtriCure to Hold from Buy and lifted its target to US$57 from US$43, expecting BoX-NoAF POAF data in Q2 2027 to be positive but flagging that earlier supportive data carries caveats, which it thinks reduces the margin for error if results or execution fall short of expectations. Revenue growth assumptions are broadly steady, moving from about 12.33% to about 12.35%, net profit margin expectations remain around 4.55%, future P/E has moved from about 94.5x to about 101.3x, and the discount rate is broadly unchanged, moving from about 7.52% to about 7.55%.

Simply Wall St raised its fair value estimate for Pulse Biosciences from US$45.25 to US$54.00 per share, a roughly 19% increase, after analysts pointed to enthusiasm around the company's nsPFA technology and first-in-human European data. BTIG, Freedom Capital and Needham describe the nanosecond pulsed field ablation platform as differentiated from traditional microsecond PFA systems, and BTIG cites European first-in-human data in 141 patients with reported procedural success of 100% at six months and 96.2% at 12 months as support for its US$70 price target. Canaccord, Mizuho and Oppenheimer each raised their price targets, with Canaccord moving from US$32 to US$43, Mizuho from US$30 to US$45 and Oppenheimer from US$30 to US$35. Oppenheimer still flags validation risk because early nsPFA data need confirmation in pivotal trials, and other firms describe Pulse Biosciences as a very early stage commercial company. The updated model also shifted the revenue growth rate from 246.85% to 218.54%, the net profit margin from 12.13% to 12.58%, the future P/E multiple from about 777x to about 1,158x, and the discount rate from 7.45% to about 7.51%.

Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.

Dexcom released its 2026 "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes, highlighting gaps in continuous glucose monitoring awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. The survey of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries found that 89% of HCPs believe CGM helps assess treatment adherence between appointments, yet 55% of surveyed Type 2 patients reported limited knowledge of the technology, and reimbursement and coverage challenges were cited by 90% of U.S. HCPs and 53% of HCPs in the other seven countries surveyed. Among existing users, 94% said CGM helps them manage diabetes more independently and 91% use CGM data to guide treatment decisions. The report also flagged an emerging intersection between CGM and GLP-1 therapies, with 58% of Type 2 patients taking GLP-1 medicines using CGM alongside their medication versus only 27% of Type 2 patients not using insulin, while half of HCPs expect increasing GLP-1 use to drive CGM adoption. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team principally sponsored by Novo Nordisk, to extend its visibility within the Type 1 diabetes community and create opportunities for real-world research, education and awareness.

The US FDA has approved Edwards Lifesciences' AUTUS surgical pulmonary valve for pediatric patients with congenital heart disease. AUTUS is the first such pulmonary valve approved for children that can be expanded as a child grows, with the expansion performed through a transcatheter procedure. The approval was based on a study that found no patients had device-related complications after 30 days and no AUTUS valve reinterventions through six months. In patients with one-year follow-up, all showed consistent outcomes, with a right ventricular outflow tract mean gradient of 40 mmHg or less, less than moderate pulmonary regurgitation, and no valve reinterventions.

Edwards Lifesciences announced that the U.S. Food and Drug Administration has approved the AUTUS Size-Adjustable Valve, the first FDA-approved surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. The valve can be expanded as a child grows through a minimally invasive transcatheter procedure, potentially reducing the need for repeat open-heart surgeries. FDA approval was based on the totality of clinical evidence from the pivotal study, which met its primary safety and effectiveness endpoints, with 100% of patients free from device-related complications through 30 days and no AUTUS valve reinterventions through six months; among patients who completed one-year follow-up, 100% showed an RVOT mean gradient of 40 mmHg or less, less than moderate pulmonary regurgitation and no valve reinterventions, with patients to be followed for 10 years. The AUTUS valve previously received FDA Breakthrough Device designation, and the approval expands Edwards' congenital treatment options, which also include SAPIEN 3, the Alterra Adaptive Prestent and pediatric atrioseptostomy catheters. CEO Bernard Zovighian called the valve a meaningful advancement for children who have historically had limited treatment options, and Dr. Emile Bacha of NewYork-Presbyterian/Columbia University Irving Medical Center, an investigator in the trial, said it gives congenital heart teams a new way to think about long-term care planning for pediatric patients who may otherwise face multiple surgeries.

Medtronic announced that the American Medical Association has approved new Category I Current Procedural Terminology codes for two of its technologies, the Altaviva implantable tibial neuromodulation device for urge urinary incontinence and the Symplicity Spyral renal denervation system for uncontrolled hypertension. The new codes, which replace existing Category III codes, take effect in January 2028. Category I codes are permanent codes assigned to procedures the AMA deems well established, widely performed across the United States, and supported by robust clinical evidence, and while they can help support physician payment and inform commercial payer coverage decisions, they do not determine coverage, reimbursement, clinical superiority, or patient access. The Altaviva device was approved by the U.S. Food and Drug Administration in September 2025 for urge urinary incontinence, a condition affecting 16 million adults in the United States, and is placed under the skin near the ankle in a minimally invasive procedure. The Symplicity Spyral system was finalized for Medicare coverage in October 2025, and Medtronic said its SPYRAL HTN global clinical program is the most comprehensive studying renal denervation, with more than 5,000 patients and experience in over 40,000 patients globally.

Retractable Technologies has declared a $1.00 per share dividend. The dividend is payable Oct. 22 to shareholders of record as of Oct. 12, which is also the ex-dividend date. The declaration applies to the company's Series II and Series III Class B preferred stock.

Medtronic reported first-quarter fiscal 2027 adjusted earnings per share of $1.45, up 15.1% year over year and ahead of the Zacks Consensus Estimate by 4.3%, while raising its full-year outlook. Revenue rose 13.7% to $9.76 billion, beating consensus by 3%, a quarter that included an extra fiscal week worth roughly $570 million in organic growth. GAAP earnings per share came in at $1.14, up from 81 cents a year earlier, and the adjusted operating margin expanded 10 basis points to 23.7%. Medtronic lifted its fiscal 2027 organic revenue growth outlook to 7.25%-7.75% from 6.75%-7.25% and raised adjusted EPS guidance to $5.94-$6.00 from $5.90-$6.00, incorporating an estimated neutral to 1% accretive foreign currency impact. The company also highlighted its recent acquisitions of Scientia Vascular and SPR Therapeutics, though shares have fallen about 6.4% since the report and estimates have trended downward, leaving the stock with a Zacks Rank #3 (Hold).

Vicor, Inogen and Alphabet were among Thursday's biggest stock gainers, while Corteva led decliners. Vicor shares jumped 10% after the company raised its Q3 sequential growth guidance to more than 30% from its previous outlook of more than 20%, reflecting increased royalties from its first non-exclusive license for vertical power delivery technology. Inogen shares surged 8% after the company agreed to divest its U.S. oxygen rental business to Rotech Healthcare for total estimated cash consideration of up to $25M, a deal expected to close in Q4 2026, alongside a long-term supply agreement with Rotech; the rental business generated $24.3M in revenue in 1H 2026, down 9.8% Y/Y, and Inogen increased its share repurchase authorization by $15M to $45M, expiring June 30, 2028. Alphabet shares edged higher 4% after Google provided a first look at Gemini 4 Argon, its latest frontier AI model, which outperformed OpenAI Astra and Anthropic Fable 5.1 and Opus 5.5 in 13 of 19 benchmarks, including a 77.9% score on DeepSWE v1.1, and will cost $2 per million input tokens and $10 per million output tokens when launched. Corteva shares dropped 64% following the planned tax-free separation of its Crop Protection business into an independent publicly traded company, Vylor, a decline reflecting the mechanical price adjustment associated with the distribution rather than a conventional sell-off, with the separation effective October 1.

Goldman Sachs added Solaria, Straumann, Scout24 and IMCD to its European Conviction List for October, while removing Naturgy, Norsk Hydro and Smith & Nephew, the broker said in a note dated Thursday. The broker did not give reasons for the removals, while its analysts cited improving earnings prospects, valuation and potential for stronger demand as reasons for the new additions. For Spanish renewable energy company Solaria, Goldman analyst Alberto Gandolfi said the market was underestimating improvements in the company's core solar business as pricing strengthens, and pointed to potential growth from data centres and energy storage. Straumann is expected to benefit from a recovery in sales, helped by improving inventories in China and stronger profit margins, analyst Richard Felton said, adding that the dental equipment maker's valuation was close to its lowest level in nearly a decade. For Swiss online marketplace Scout24, analyst Adam Berlin said new products could support growth in private subscribers, putting his estimates above market expectations, and he also sees potential for the company to return more cash to shareholders than expected. IMCD could be approaching a turning point in volumes, while its more specialised product mix should help prices hold up better than expected, analyst Suhasini Varanasi said. Goldman said additions to or removals from its Conviction Lists do not change its underlying investment ratings. Elsewhere, Goldman kept Swedish engineering group Trelleborg on the list with a Buy rating and saw 20% upside, cut its third-quarter 2026 sales estimate by 50 basis points and adjusted EBITA forecast by 140 basis points, and retained a buy rating on BMW following the automaker's Capital Markets Day, seeing 48% upside. The bank upgraded Iberdrola to buy from neutral and raised its price target by 19% to €25 from €21, upgraded AJ Bell to neutral from sell, and remained buy-rated on French steel tube maker Vallourec.

PHC Holdings confirmed it has received an initial, non-binding takeover proposal from Toho Holdings, sending its shares up 13.6% to 1,625 yen on Thursday, an intraday high of 1,644 yen and their highest level since November 25, 2022. Toho, a Japanese pharmaceutical wholesaler, has proposed acquiring PHC for more than ¥200 billion, or $1.3 billion, and is conducting due diligence, according to Bloomberg, which cited people familiar with the matter. That reported deal value compares with PHC's market capitalization of roughly ¥182 billion, and the eventual tender offer price is expected to include a premium. Toho is currently the only prospective buyer in concrete discussions, though domestic investment funds have also shown interest, and both Toho and KKR, PHC's largest shareholder with about a 38% stake, have appointed financial advisers. PHC said no decision has been made on a transaction and that it will disclose further information if a matter requiring disclosure is decided.

Tandem Diabetes Care has launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel. The small, iPhone-controlled pump uses Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes, and it offers flexible wear options and a 200-unit cartridge. The international rollout broadens Tandem's technology ecosystem for people living with diabetes outside the United States and supports the company's near-term catalyst of international expansion and ecosystem adoption. Tandem's narrative projects $1.4 billion in revenue and $63.4 million in earnings by 2029, requiring 10.3% yearly revenue growth and a $157.9 million earnings increase from -$94.5 million today, while some analysts assume revenue could reach about US$1.6 billion and earnings US$170.9 million.

PHC Holdings, which manufactures medical-related equipment, said on the 1st that it has received a non-binding initial acquisition proposal from Toho Holdings, a major pharmaceutical wholesaler. The announcement followed a report the previous day, and Toho Holdings also said it is "considering the matter mentioned in the article," though it said no decision has been made at this point. According to a Bloomberg report on September 30, Toho Holdings aims to acquire all shares through a tender offer, with the acquisition amount expected to exceed 200 billion yen. Domestic investment funds also showed interest in acquiring PHC, but Toho is currently the only buyer candidate in concrete acquisition talks. PHC's largest shareholder is the U.S. investment firm KKR, which holds about 38 percent. According to the report, PHC and KKR have each hired financial advisors and have been seeking a buyer for PHC in line with KKR's exit.

Abbott Laboratories has launched SimpleScreen CRC in the United States, an FDA-approved blood-based colorectal cancer screening test aimed at average-risk adults who decline traditional screening methods. The rollout comes alongside new clinical use of Abbott's Volt PFA system for atrial fibrillation and the continuation of its long-running dividend stream. Abbott's shares have fallen about 10.2% over the past month while gaining 9.5% over 90 days, leaving the 1 year total shareholder return down 22.9%, the 3 year total shareholder return up 12.2% and the 5 year total shareholder return slightly negative at 4.0%, with the stock at US$100.95. The most followed analyst narrative puts Abbott's fair value at $120.26, implying the shares are 16% undervalued, while the SWS DCF model points to a future cash flow value of $80.68. That narrative assumes scaling of the cancer diagnostics portfolio following the Exact Sciences acquisition, with 13% comparable growth in early 2026, care gap programs ramping in the second half and an expected contribution of about US$3b of 2026 sales, though ongoing Nutrition legal settlements and higher Libre expansion spending remain pressure points.

Smith+Nephew has launched the EVOS PELVIC Plating System, expanding its EVOS trauma platform into pelvic and acetabular fracture management. The system is designed to address a broad range of pelvic and acetabular fracture patterns, with pre-contoured options for the posterior wall, quadrilateral surface and pubic symphysis, along with locking and non-locking utility plates, and a dedicated cannulated screw platform and specialized instruments for fracture exposure, reduction and implant placement. The company said the integrated design allows surgeons to obtain and fine-tune fracture reduction before maintaining fixation through the healing process, which it believes could make complex pelvic procedures more efficient and reproducible. The EVOS PELVIC System is currently available in the United States, while timing and availability in other markets will vary. According to Data Insights Reports, the global pelvic trauma management market was valued at $2.81 billion in 2025 and is projected to reach $4.79 billion by 2034, expanding at a 6.1% CAGR. Smith+Nephew, which has a market capitalization of $11.37 billion, in August announced the launch of the FLOW FLEXTEND COBLATION Wand, a new RF resection technology for complex hip procedures.

Integra LifeSciences Holdings Corporation reported second-quarter 2026 adjusted EPS growth of 24.4% year over year, exceeding management's guidance range, as the company's Specialty Surgery segment grew 1.6% organically to $309.3 million. Adjusted gross margin improved 60 basis points to 61.3% and adjusted EBITDA margin expanded 160 basis points to 18.7%, while management kept its full-year 2026 adjusted EPS guidance unchanged at $2.40-$2.50. The company's Tissue Reconstruction segment posted revenues of $109.5 million, down 2% organically, as DuraSorb growth and PriMatrix gains were offset by lower Integra Skin and MicroMatrix sales. Integra ended the quarter with total liquidity of about $496 million, including $274 million of cash and short-term investments, but net debt remained high at $1.60 billion and total leverage of 4.1X stayed above management's 2.5X-3.5X target range. Management also lowered full-year reported revenue guidance to $1.654-$1.695 billion from $1.662-$1.702 billion solely because of a stronger U.S. dollar.

Abbott announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older at average risk for the disease. Developed and manufactured by Freenome and exclusively commercialized by Abbott, SimpleScreen CRC joins the Cologuard Plus test in Abbott's colorectal cancer screening portfolio, giving healthcare providers both stool- and blood-based options. The test was evaluated in PREEMPT CRC, the largest prospective clinical validation study for a blood-based colorectal cancer screening test, which enrolled more than 48,000 asymptomatic, average-risk adults ages 45 to 85. In a prespecified analysis adjusted to match the U.S. Census, SimpleScreen CRC demonstrated 81.1% overall sensitivity for colorectal cancer, including 63.5% sensitivity for Stage I CRC, 13.7% sensitivity for advanced precancerous lesions, and 90.4% specificity for advanced colorectal neoplasia. SimpleScreen CRC is covered by Medicare, with no out-of-pocket costs for eligible patients with Medicare Part B, while Medicare Advantage patients may have out-of-pocket costs.

Balance Medical announced on September 30 that as of September 29, 2026, the company had repurchased 1.3 million shares, accounting for 0.9428% of total share capital, with a repurchase amount of 99.99 million yuan and a repurchase price range of 67.76 yuan to 85.45 yuan per share. In the first half of 2026, Balance Medical achieved revenue of 254 million yuan and net profit attributable to the parent of 43.89 million yuan.

Minsheng Health announced that the company has received the Drug Supplementary Application Approval Notice for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The drug is indicated for primary and secondary osteoarthritis. The company stated that obtaining this drug approval will help enrich its product portfolio and enhance market competitiveness. The company also cautioned that pharmaceutical sales are susceptible to industry policy changes, market competition, and other factors, and therefore involve uncertainty.

Minsheng Health announced on September 30 that the company received the Drug Supplementary Application Approval Notice for Glucosamine Sulfate Capsules issued by the National Medical Products Administration. The drug is indicated for primary and secondary osteoarthritis, with the main ingredient being glucosamine sulfate sodium chloride. The specification is 0.25 grams calculated as glucosamine sulfate, or 0.314 grams calculated as glucosamine sulfate sodium chloride. The drug has a shelf life of 18 months, and the approval number is H20255903. In the first half of 2026, Minsheng Health achieved revenue of 535 million yuan and net profit attributable to the parent company of 83.39 million yuan.

Nvidia authorized an additional $150 billion for its share buyback program, bringing the total authorization to $235 billion, and the graphics chip designer's shares rose 2.7% on Monday. Pacific Biosciences of California climbed 5.8% after genomics provider Sampled announced a five-year contract worth up to $27.1 million from the U.S. Department of Veterans Affairs to support research using PacBio Revio sequencing systems. Palo Alto Networks gained 5.1% after BTIG raised its price target on the cybersecurity platform provider to $425 from $404 and reiterated a Buy rating following discussions with management. Teleflex rose 4.5% after BofA Securities upgraded the medical technology company's stock from Neutral to Buy and raised its price target.

Nano-X Imaging Ltd. is advancing its Nanox.AI medical imaging analytics subsidiary on two fronts this month, led by an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution that includes minimum annual license commitments. The deal targets a UK market where approximately 86,000 vertebral fragility fractures occur annually, with most remaining undiagnosed. Separately, an optimization project with Intel demonstrates a path for Nanox.AI's imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud. The company said routine CT imaging can capture information related to the spine, coronary arteries, liver and other areas beyond the original clinical indication, creating an opportunity to support clinical evaluation of findings that might otherwise go unnoticed.

Beta Bionics announced a partnership with Senseonics to expand compatibility between its automated insulin delivery platform and Senseonics' continuous glucose monitoring technology. The integrated iLet and Eversense 365 system is expected to launch commercially in the fourth quarter of 2026, after which the iLet is expected to support Dexcom G6, Dexcom G7, Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365, which Beta Bionics expects will make the iLet compatible with more CGM manufacturers than any other AID system. Beta Bionics also intends to integrate its next-generation mint AID system with Eversense 365 in the future. Following the Sept. 22 announcement, shares of BBNX lost more than 8% in the next trading session and have lost 32.6% year to date, compared with the industry's 4.9% decline, leaving the company with a market capitalization of $967.7 million. Separately, BBNX recently secured FDA clearance for its Mint patch pump and unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review.

Integer Holdings Corporation has entered into a definitive agreement to be acquired by affiliates of Kohlberg Kravis Roberts & Co. L.P., with each eligible share convertible into the right to receive $127 in cash at closing. The transaction, announced on Aug. 2, 2026, is not subject to a financing condition, and the buyer has obtained equity and debt financing commitments; completion remains subject to customary conditions, including approval by holders of a majority of outstanding shares and required regulatory clearances. The agreement provides for a $307 million parent termination fee in certain circumstances involving a buyer breach or failure to complete the transaction when required, and if completed, Integer Holdings would become a wholly owned subsidiary of the buyer and its shares would be delisted from the NYSE. The medical device outsourcing manufacturer, which has a market capitalization of $4.3 billion, reported mixed second-quarter 2026 results, with revenues declining 2.6% year over year to $464.1 million and adjusted earnings per share rising 3.2%. Cardio & Vascular sales fell 2% to $280.3 million on lower-than-expected adoption of two new electrophysiology products, while Cardiac Rhythm Management & Neuromodulation sales rose 1% to $173.7 million, and gross margin declined to 24.3% from 27.1% a year earlier. The Zacks Consensus Estimate for third-quarter 2026 revenues is $457.3 million, indicating a 2.2% decline from the year-ago quarter, with earnings pegged at $1.65 per share, implying a 7.8% decline.

IBA has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena, known as IFO, to provide a turnkey proton therapy solution in Rome, Italy, the first gantry-based proton therapy system available in central and southern Italy. Following a public tender, IBA and its partners Cecchini SRL and Gowen SRL, construction companies and RTI members, were selected by IFO to deliver a turnkey compact gantry-based ProteusONE system at the Istituti Fisioterapici Ospitalieri center in Rome, for both pediatric and adult patients. The contract covers the latest-generation ProteusONE system, design, build, installation, a comprehensive training and education program, and a one-year operation and maintenance agreement, with IFO expecting to start treating patients in 2030. The typical end user price of a ProteusONE system with a multiyear maintenance contract ranges between 35 million euros and 45 million euros. Henri de Romree, Deputy Chief Executive Officer of IBA, said the project will make gantry-based proton therapy available to patients in central and southern Italy for the first time, while Giuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO, called it an important step forward in expanding access to advanced cancer care in the region.

Namwiwat Medical Corporation, or NAM, has announced a five-pillar growth strategy to expand from a developer and distributor of medical device products into a broader provider of healthcare innovations and solutions. Chief Executive Officer Wirot Chaitherdkiat said the five engines are expanding the product portfolio from upstream to downstream, brand building, overseas market expansion, the use of strategic partnerships, and efficient cost management, alongside continuous development of medical innovations. On overseas markets, NAM is expanding its footprint through subsidiaries in Malaysia and Italy, as well as setting up an SKD parts assembly base in Indonesia with a local partner. Revenue from overseas currently accounts for about 5% and the company expects it to rise significantly over the next three years. For its business targets, NAM aims for 2026 revenue of 2.4 billion baht, growing 10–12% from the previous year, while pressing ahead with its Jump+ plan, with a net profit target of 380 million baht in 2028.